ARTICLE | Company News

Genzyme metabolic news

July 26, 2010 7:00 AM UTC

Genzyme disclosed in its 2Q10 earnings that it remains on track to transfer the fill/finish for thyroid cancer treatment Thyrogen thyrotropin alfa and Fabrazyme agalsidase beta for Fabry's disease out of its Allston, Mass., facility by the November deadline agreed to with FDA in a Consent Decree regarding deficiencies at the plant. Genzyme has contracted Hospira Inc. (NYSE:HSP, Lake Forest, Ill.) to perform fill/finish for the products (see BioCentury, May 31 & Jan. 11).

The company also said two bioreactors at its new Framingham, Mass., plant are now operational, with engineering runs to begin in September and approval anticipated in late 2011. ...